Bevacizumab plus Interferon-α versus Sunitinib for First-Line Treatment of Renal Cell Carcinoma in Italy: A Cost-Minimization Analysis

By Ravasio Roberto   Ortega Cinzia   Sabbatini Roberto   Porta Camillo  

Clinical Drug Investigation, Vol. 31, Iss. 7, 2011-07 ,pp. : 507-517

Adis International

Access to resources Recommend Favorite

Cost-Effectiveness of the Addition of Rituximab to CHOP Chemotherapy in First-Line Treatment for Diffuse Large B-Cell Lymphoma in a Population-Based Observational Cohort in British Columbia, Canada

By Johnston Karissa M.   Marra Carlo A.   Connors Joseph M.   Najafzadeh Mehdi   Sehn Laurie   Peacock Stuart J.  

Value in Health, Vol. 13, Iss. 6, 2010-09 ,pp. : 703-711

Blackwell Publishing

Access to resources Recommend Favorite

First-line sunitinib cost-effective alternative to interferon-α in renal cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 561, 2008-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

An Evaluation of the Cost-Effectiveness of Rituximab in Combination with Chemotherapy for the First-Line Treatment of Follicular Non-Hodgkin's Lymphoma in the UK

By Ray Joshua A.   Carr Emma   Lewis Gavin   Marcus Robert  

Value in Health, Vol. 13, Iss. 4, 2010-06 ,pp. : 346-357

Blackwell Publishing

Access to resources Recommend Favorite

Sunitinib malate for the treatment of renal cell carcinoma

By Wood Lori  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 9, 2012-06 ,pp. : 1323-1336

Informa Healthcare

Access to resources Recommend Favorite